Using 68Ga-FAPI PET/CT to visualize malignant tumors
The Diagnostic Efficiency of 68Ga-FAPI PET/CT in Malignant Tumors
This study is testing a new imaging method using a special agent to see if it can help doctors better spot and understand malignant tumors, especially in gastrointestinal cancers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 88 Years |
| Sex | All |
| Sponsor | Zhongnan Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05034146 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of a novel imaging agent, 68Ga-FAPI, in conjunction with PET/CT scans to enhance the visualization of malignant tumors. The study aims to evaluate the effectiveness of this molecular imaging technique in detecting and characterizing tumors, particularly in gastrointestinal cancers. By targeting fibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts, the trial seeks to provide more accurate diagnostic information compared to traditional imaging methods. The research will involve patients with suspected or confirmed malignant tumors to assess the advantages of this approach over existing imaging modalities.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with suspected or confirmed malignant tumors.
Not a fit: Patients who are pregnant, planning to become pregnant, or have allergies to multiple drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and better treatment planning for patients with malignant tumors.
How similar studies have performed: Previous studies have shown favorable diagnostic efficiency for 68Ga-FAPI in small samples, but this trial aims to confirm its advantages in a larger population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Volunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor Exclusion Criteria: Female patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month
Where this trial is running
Wuhan, Hubei
- Zhongnan Hospital of Wuhan University — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Yong He, MD, PhD — Zhongnan Hospital
- Study coordinator: Yong He, MD, PhD
- Email: vincentheyong@163.com
- Phone: +86-27-67812698
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.